XML 51 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1
Borrowings - Additional Information (Detail)
 12 Months Ended
May 13, 2021
USD ($)
Mar. 07, 2019
USD ($)
$ / shares
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Mar. 31, 2023
USD ($)
Mar. 30, 2023
USD ($)
Debt Instrument [Line Items]            
Amortization for remaining debt issuance costs and discount       $ 1,900,000    
Amortization of debt issuance costs and discount     $ 1,726,000 2,994,000    
Loan Agreement Amendment            
Debt Instrument [Line Items]            
Prepayment fee payable           $ 262,500
Final payment payable under loan agreement           1,382,500
Loan Agreement Amendment | GlaxoSmithKline Intellectual Property            
Debt Instrument [Line Items]            
Upfront payment $ 90,000,000          
Loan Agreement Amendment | Hercules Capital Inc. and Silicon Valley Bank            
Debt Instrument [Line Items]            
Prepayment fee payable         $ 35,000,000  
Loan Agreement Amendment | Hercules Capital Incorporated And Silicon Valley Bank And Other Lenders            
Debt Instrument [Line Items]            
Loan payable (Note 8)           $ 35,400,000
Senior Convertible Note Purchase Agreement            
Debt Instrument [Line Items]            
Face amount   $ 16,000,000        
Notes maturity date     Mar. 15, 2025      
Date of issuance and sale of notes   Mar. 07, 2019        
Proceeds from debt, net of issuance costs   $ 14,700,000        
Payment of debt issuance costs   $ 1,300,000        
Purchase price as percentage of principal amount   100.00%        
Interest rate   6.00%        
Payment terms     The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased. The March 2019 Notes constitute general, senior unsecured obligations of the Company.      
Senior convertible notes     $ 13,700,000 12,000,000    
Bifurcated embedded conversion option derivative liability     0 200,000    
Derivative, fair value     7,000,000      
Gain (loss) on fair value adjustment of derivative liability     200,000 200,000    
Amortization of debt issuance costs and discount     $ 1,700,000 $ 1,000,000    
Conversion terms     holder of the March 2019 Notes may convert their March 2019 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 into shares of the Company’s common stock.      
Conversion rate, number of shares to be issued per $1000 of principal (in shares)   73.9096        
Principal amount of notes used as the denominator for conversion into notes   $ 1,000        
Initial conversion price of notes | $ / shares   $ 13.53        
Conversion rate, number of shares to be issued per $1000 of principal (in shares) after adjustment to certain events   81        
Principal amount of notes used as the denominator for conversion into notes after adjustment of certain events   $ 1,000